

Objectives: In this study, it was aimed to present a case who was followed up with the diagnosis of ADHD since childhood and developed psychosis after a recent traumatic life event.

Methods: A 19-year-old male patient was consulted because of his complaints of persecution delusions, and disorganized speech that started 2 years ago. It was learned that the first psychiatry application of the patient was 10 years ago with complaints of impulsivity, aggression, increased psychomotor movements, and methylphenidate treatment was started during this period. The patient, whose current clinical picture was evaluated as psychosis, was discharged after the symptoms subsided with paliperidone depot 100mg/month treatment after hospitalization. It is understood that his psychotic complaints completely regressed in the follow-ups.

Results: It is stated that approximately 80% of adult ADHD cases have at least one accompanying psychiatric disorder. However, there are limited studies in the literature on the relationship between psychotic disorders and ADHD.

Conclusions: Recent studies indicate that beyond the fact that ADHD is a feature of the schizophrenia prodrome, ADHD diagnosis may be associated with an increased risk of psychosis in the future. Therefore, this association can be better clarified in further studies on comorbidities.

Disclosure: No significant relationships.

Keywords: Psychosis; Attention Deficit; hyperactivity; comorbidity

EPV0303

Relationship between cannabis use and schizophrenia

J.J. Vazquez Vazquez^{1*}, M.M. Gutiérrez Rodríguez², M.D.L.A. Corral Y Alonso², C. Moreno Menguiano² and F. García Sánchez²

¹Centro de Salud Mental de Móstoles / Hospital Universitario de Móstoles, Psychiatry, Móstoles, Spain and ²HOSPITAL UNIVERSITARIO DE MÓSTOLES, Psychiatry, MÓSTOLES (MADRID), Spain

*Corresponding author.

doi: 10.1192/j.eurpsy.2022.1191

Introduction: Numerous studies have shown evidence that cannabis use increases the appearance of psychotic symptoms and disorders, and worsens the course of the disease in those with schizophrenia. However, a causal relationship between cannabis and schizophrenia has not been well established yet.

Objectives: In this presentation we try to review the relationship between cannabis use and prevalence of schizophrenia.

Methods: We performed a search of Medline looking for systematic reviews and methodologically robust studies in the field published in English in the last 5 years.

Results: A number of studies, both cross-sectional and prospective, find a prevalence of schizophrenia several times higher among cannabis users than in non-users. This association becomes stronger the lower the age of cannabis use onset, the higher the amount consumed and the higher the THC concentration are. Half of the patients with a cannabis-induced psychotic disorder turn into a diagnosis of schizophrenia within a few years. So far, it has not been

possible to demonstrate a global increased prevalence of schizophrenia in relation to the increase of cannabis use in the population in recent decades.

Conclusions: Cannabis and schizophrenia have a complex relationship model; we still cannot clearly establish whether it is causal or the first works as a trigger for pathology in vulnerable subjects.

Disclosure: No significant relationships.

Keywords: Cannabis; relationship; psychosis; schizophrenia

EPV0304

Resistant schizophrenia in a patient with oculocutaneous albinism successfully treated with clozapine

A. Jelti*, F. N'Sabi, F. Kennab and M. Barrimi

Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, University Mohammed Premier, Department Of Psychiatry, Oujda, Morocco

*Corresponding author.

doi: 10.1192/j.eurpsy.2022.1192

Introduction: Several studies have shown an association between oculocutaneous albinism and several neuropsychiatric entities, including schizophrenia.

We present through this work the first case of resistant schizophrenia described in this type of patient.

Objectives: Demonstrate the safety of clozapine in albinos patients and discuss the linkage between the two disorders.

Methods: We describe the case of a 23-year-old patient with oculocutaneous albinism who developed treatment-resistant schizophrenia, successfully treated with clozapine.

Results: We received the patient referred by his private psychiatrist, after the absence of improvement despite the use of several first and second generation antipsychotics, alone and in combination, at therapeutic doses, with good compliance and for a duration of more than 3 months.

The onset of psychotic symptoms was at the age of 18 years, and the evolution was continuous.

On admission, the patient was agitated and assessment of thought content were difficult due to intellectual disorganization. The initial PANSS score was assessed at 120. The somatic examination was normal, except for generalized hypopigmentation and horizontal and rotatory nystagmus. A biological workup, MRI, and electroencephalogram revealed no abnormalities.

The diagnosis of resistant schizophrenia was retained and the patient was put on clozapine 12.5 mg/d with progressive titration to a dose of 400 mg at the 6th week, with marked improvement; the patient became motor calm, with understandable speech and adapted responses, the PANSS score at the 2nd month decreased markedly by 33 (from 120 to 87).

Conclusions: This case report suggests that clozapine can be safely introduced in patients with oculocutaneous albinism.

Disclosure: No significant relationships.

Keywords: Oculocutaneous albinism; resistant schizophrenia; clozapine